SCHEMBL22388183

SCHEMBL22388183

CCN(c1ccc(CCC(C)C)cc1)C(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESRRG P62508 2/20 0.38
IGLV6-57 P01721 1/20 0.37
ALDH1A1 P00352 5/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
MAPT P10636 3/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MCL1 Q07820 2/20 0.35
AR P10275 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.33
BCHE P06276 1/20 0.33
AOC3 Q16853 2/20 0.33
CHRM2 P08172 1/20 0.32
HTR1A P08908 1/20 0.32
ADRA2A P08913 1/20 0.32
CHRM1 P11229 1/20 0.32
DRD1 P21728 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26788754 0.81 ALDH1A1 (0.40) IGLV6-57ALDH1A1L3MBTL1MAPTLMNA
SCHEMBL22388178 0.77 KDM4E (0.39) ALDH1A1TDP1BCHEAOC3
SCHEMBL8080450 0.77 HTT (0.41) HTTSMN1; SMN2AOC3
SCHEMBL13886433 0.76 ALDH1A1 (0.54) ALDH1A1TDP1
SCHEMBL13168760 0.76 AOC3 (0.44) ALDH1A1L3MBTL1MAPTTDP1MEN1
SCHEMBL27374360 0.76 AOC3 (0.44) ALDH1A1L3MBTL1MAPTTDP1MEN1
SCHEMBL24198828 0.74 ESR1 (0.44) ESRRGIGLV6-57ALDH1A1L3MBTL1MAPT
SCHEMBL22012736 0.74 ALDH1A1 (0.42) ESRRGIGLV6-57ALDH1A1L3MBTL1MAPT
SCHEMBL13091139 0.74 IGLV6-57 (0.45) IGLV6-57ALDH1A1L3MBTL1MAPTLMNA
SCHEMBL24300108 0.74 ESRRG (0.34) ESRRGIGLV6-57ALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827656-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2023-11-28 US disclosed
US-11827656-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2023-11-28 US disclosed
US-20220073538-A1 Immunoproteasome Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2022-03-10 US disclosed
US-11225493-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2022-01-18 US disclosed
US-20200277312-A1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC. 2020-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827656-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 ESRRG 3698/4885IGLV6-57 2052/4885ALDH1A1 3439/4885
US-20200277312-A1 IMMUNOPROTEASOME INHIBITORS PSMC2, PSMB7, PSMB2 ESRRG 3698/4885IGLV6-57 2052/4885ALDH1A1 3439/4885
US-11225493-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 ESRRG 3698/4885IGLV6-57 2052/4885ALDH1A1 3439/4885
US-20220073538-A1 Immunoproteasome Inhibitors PSMC2, PSMB7, PSMB2 ESRRG 3698/4885IGLV6-57 2052/4885ALDH1A1 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.